Scholarlink

<p>This letter addresses the recent study by Sohn et al., which compared moderate-intensity atorvastatin plus ezetimibe with high-intensity atorvastatin in patients with angina undergoing PCI. We emphasize key limitations, including the absence of LDL-C values, potential residual confounding, and the small CKD subgroup sample size. Furthermore, adherence and safety outcomes were not adequately assessed. While the study supports non-inferiority of combination therapy, further prospective research is needed to clarify optimal lipid-lowering strategies in this high-risk population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Optimizing Lipid-Lowering Strategies Beyond Current Evidence

  • 期刊论文

  • 发表日期：

    2025年9月12日

查看全文
  • Mucahit Yetim,
  • Abdülmelik Birgün,
  • Macit Kalçık

摘要

This letter addresses the recent study by Sohn et al., which compared moderate-intensity atorvastatin plus ezetimibe with high-intensity atorvastatin in patients with angina undergoing PCI. We emphasize key limitations, including the absence of LDL-C values, potential residual confounding, and the small CKD subgroup sample size. Furthermore, adherence and safety outcomes were not adequately assessed. While the study supports non-inferiority of combination therapy, further prospective research is needed to clarify optimal lipid-lowering strategies in this high-risk population.